Danish medtech company prepares for phase III trials in the US
The medtech company Medtrace has received permission to bypass phase 1 and 2 in the US on the strength of its existing research and is now preparing to begin phase III trials. The company is also looking to raise capital.
BY ELIZABETH MØNSTED JOHANSEN
It is not a daily occurrence that companies are permitted to shave off two whole clinical phases from their development course, but that is precisely what has happened for the small Danish medtech company, Medtrace.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
